Abstracts Archive - Page 781 of 2425 - ACR Meeting Abstracts

Abstract Number: 1895 • ACR Convergence 2020
Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)
Maria Llop¹, Mireia Moreno², Jordi Gratacós³, Victoria Navarro-Compán⁴, Eugenio De Miguel⁵, Pilar Font⁶, Teresa Clavaguera⁷, Luis Francisco Linares⁸, Beatriz Joven⁹ and Xavier Juanola¹⁰, ¹Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, ²Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, ³University Hospital Parc Tauli Sabadell, Barcelona, Spain, ⁴Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁷Hospital Universitari Trueta, Girona, Spain, ⁸Hospital de la Arrixaca, Murcia, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
Abstract Number: 1896 • ACR Convergence 2020
No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Sofia Ramiro², Pedro M Machado³, Désirée van der Heijde⁴ and Floris van Gaalen⁵, ¹Leiden University Medical Center, Coimbra, Portugal, ²Leiden University Medical Center, Bunde, Netherlands, ³University College London, London, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA) it has been hypothesized that inflammation-driven bone loss triggers bone repair but at anatomically distinct sites of the same…
Abstract Number: 1897 • ACR Convergence 2020
Trends in Hospitalizations for Vertebral Compression Fractures in Ankylosing Spondylitis: Data from the National Inpatient Sample 2001-2014
Anish Paudel¹, Rashmi Dhital², Dilli Poudel³, Anthony Donato¹ and Paras Karmacharya⁴, ¹Reading Hospital and Medical Center, West Reading, PA, ²Reading Hospital and Medical Center, West Reading, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester MN, ROCHESTER, MN
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the spine, leading to syndesmophyte formation, ankylosis, and osteoporosis. These factors have been associated…
Abstract Number: 1898 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau¹, Denis Choquette², Louis Bessette³, Isabelle Ferdinand¹, Boulos Haraoui⁴, Frédéric Massicotte¹, Jean-Pierre Pelletier², Jean-Pierre Raynauld², Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Édith Villeneuve¹ and Louis Coupal¹, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Institut de Rhumatologie de Montréal, Montreal, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing.…
Abstract Number: 1899 • ACR Convergence 2020
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Zhixiu Li¹, Mohammad Khan², Sjef van der Linden³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Matthew Brown⁷ and Muhammad Khan⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Kent State University, Kent, OH, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁸Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: To investigate life expectancy of a Swiss cohort of patients with ankylosing spondylitis (AS) versus general population during 35 years of longitudinal follow up,…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 1901 • ACR Convergence 2020
Clinical Characteristics of Importance to Outcome in Patients with Axial Spondyloarthritis: A Prospective Cohort Study
Rikke Asmussen Andreasen¹, Xenofon Baraliakos², Lars Erik Kristensen³, Kenneth Egstrup⁴, Vibeke Strand⁵, Hans Christian Horn⁶, Jimmi Wied⁶, Berit Schiøttz-Christensen⁷, Claus Aalykke¹, Inger Marie Hansen¹, Torkell Juulsgaard Ellingsen⁸ and Robin Christensen⁹, ¹Odense University Hospital, Svendborg, Svendborg, Denmark, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Odense University Hospital Svendborg, Svendborg, Denmark, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Odense University Hospital, Odense, Denmark, ⁷Spine Centre of Southern Denmark. Hospital lillebaelt, Middelfart, Denmark, ⁸Rheumatology Research Unit, Dept of Rheumatology Odense University Hospital, Odense C, Denmark, ⁹Musculoskeletal Statistics Unit, The Parker Institute/Odense University Hospital, Copenhagen F, Denmark
Background/Purpose: Despite better control of inflammation, many patients with axial spondyloarthritis (axSpA) still report pain, although they could be in remission. This suggests that in…
Abstract Number: 1902 • ACR Convergence 2020
Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis
Fumio Hirano¹, Robert Landewé², Floris van Gaalen³, Désirée van der Heijde⁴, Cecile Gaujoux-Viala⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ²Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In rheumatic and musculoskeletal diseases, physician global assessment (PhGA) is a major factor of treatment decision. However, it is not well-known which disease manifestations…
Abstract Number: 1903 • ACR Convergence 2020
Assessment of Global DNA Methylation in Peripheral Blood Cell Subpopulations of Patients with Axial Spondyloarthritis : Preliminary Results
Eric Toussirot¹, Sebastien Pasquereau², Charline Vauchy³, Zeina Nehme⁴, Daniel Wendling⁵, Jean Charles Balbalnc⁶, Caroline Laheurte⁷, Marc Puyraveau⁸ and Georges Herbein², ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²Pathogens & Inflammation/EPILAB Laboratory, UPRES EA 4266, Besancon, France, ³INSERM CIC-1431, Besancon, France, ⁴Pathogens & Inflammation/EPILAB Laboratory, UPRES EA 4266, Besancon, ⁵CHU Besançon, department of rheumatology, Besancon, France, ⁶Rhumatologie, Trevenans, France, ⁷Plateforme de biomonitring, Besancon, France, ⁸uMETh & INSERM CIC 1431, Besancon, France
Background/Purpose: Axial spondyloarthritis (ax-SpA) corresponds to a group of chronic inflammatory disease mainly affecting the axial skeleton. TNF and IL-17A have been identified as key…
Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Xenofon Baraliakos¹, Rebecca Bolce², David Sandoval², Soyi Liu-Leage³, Vladimir Geneus³, David Adams³, Atul Deodhar⁴, Jessica Walsh⁵ and Joachim Sieper⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Oregon Health & Science University, Portland, OR, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
Abstract Number: 1905 • ACR Convergence 2020
Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis
Yuzuru Yamamoto¹, Takaichi Okano², Takumi Nagamoto², Yoshikazu Fujikawa³, Yoshihide Ichise², Hirotaka Yamada², Ikuko Naka², Yo Ueda⁴, Kengo Akashi⁵, Sho Sendo⁶, Akira Onishi⁵, Jun Saegusa⁷ and Akio Morinobu⁵, ¹Kobe University, Kobe-city, Japan, ²Kobe University, Kobe, Japan, ³Kobe University, Kobe city, Japan, ⁴Kobe UniversityRheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan, ⁶Kobe University, Kobe, ⁷Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and…
Abstract Number: 1906 • ACR Convergence 2020
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
Hana Storkanova¹, Lenka Storkanova², Sabina Oreska³, Maja Spiritovic⁴, Barbora Hermankova⁵, Radim Becvar¹, Karel Pavelka⁶, Jiří Vencovský⁶, Jörg HW Distler⁷, Ladislav Šenolt⁶ and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ⁴Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…
Abstract Number: 1907 • ACR Convergence 2020
DNASE1L3 R206C Polymorphism, a Systemic Sclerosis Risk Factor, Causes Impaired Digestion of Genomic DNA in Apoptosis-derived Extracellular Vesicles
Brian Skaug¹, Julio Charles¹, Jacob Couturier², Dorothy Lewis², Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of Texas Houston McGovern Medical School, Division of Infectious Diseases, Houston, TX, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Two independent studies on genetic risk factors for systemic sclerosis (SSc) identified a polymorphism of Deoxyribonuclease 1-like 3 (DNASE1L3) associated with increased SSc risk. …
Abstract Number: 1908 • ACR Convergence 2020
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Yuki Kudo¹, Masaru Kato², Yuhei Shibata¹, Michihito Kono², Yuichiro Fujieda², Olga Amengual², Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) occurs either primarily or in association with other diseases such as connective tissue diseases. PAH associated with systemic sclerosis (SSc-PAH)…
Abstract Number: 1909 • ACR Convergence 2020
High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Nicolas Wisniacki³, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: Simultaneous analysis of multiple proteins in biological fluids offers insight into the pathogenesis of SSc. Here, we report a proteomic analysis of plasma and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].